Lenalid 5

Lenalidomide is a thalidomide-derived oral immunomodulatory agent with antineoplastic properties, primarily indicated for the treatment of multiple myeloma in newly diagnosed, relapsed, or refractory settings, as well as maintenance therapy following autologous stem cell transplantation, and for transfusion-dependent anemia in patients with low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality.[1][2] First approved by the U.S. Food and Drug Administration in December 2005 for the myelodysplastic syndrome indication, its approvals expanded through subsequent clinical trials demonstrating prolonged progression-free survival and overall survival in multiple myeloma patients compared to placebo or alternative therapies.[3][4] Lenalidomide exerts its effects by binding to the E3 ubiquitin ligase cereblon, promoting the proteasomal degradation of transcription factors such as Ikaros and Aiolos, which inhibits cancer cell proliferation, enhances T-cell and natural killer cell-mediated cytotoxicity, and suppresses pro-inflammatory cytokines in the tumor microenvironment.[5] In multiple myeloma, combination regimens with dexamethasone or bortezomib have yielded overall response rates exceeding 60% in relapsed patients and significantly improved three-year progression-free survival rates to approximately 53% versus 36% with controls.[6][7] Despite its efficacy, lenalidomide carries substantial risks, including severe neutropenia, th